Does chronic smoking influence fibrinolytic potential in Type 1 diabetes mellitus?

Diabetic Medicine

Volumn 15, Issue 8, 1998, Pages 683-687

  Simpson, A J ^a,c   Booth, N A ^b   Moore, N R ^b   Gray, R S ^a  

^a ST JOHN'S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Fibrinolysis; Plasma; Plasminogen activator inhibitor type 1; Platelets; Smoking; Tissue type plasminogen activator; Type 1 diabetes

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; MALE; SMOKING;

ADULT; BLOOD GLUCOSE; BLOOD PLATELETS; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMOKING; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0031868930     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199808)15:8<683::AID-DIA643>3.0.CO;2-E     Document Type: Article

References (40)

1. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
2. Booth NA. The natural inhibitors of fibrinolysis. In. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis, 3rd edn. Edinburgh: Churchill Livingstone, 1994: 699-717.
3. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thrombosis and Haemostesis 1993; 70: 138-143.
4. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc 1979; 241: 2035-2038.
5. Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964-966.
6. Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O'Donnell M, O'Connor B, Noble MI, Leslie DG. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 1994; 43: 831-835.
7. Gough SCL, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabetic Med 1991; 8: 898-905.
8. Simpson AJ, Gray RS, Moore NR, Booth NA. The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol 1997; 97: 208-213.
9. Booth NA, Simpson AJ, Croll AM, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333.
10. Declerck PJ, Alessi MC, Verstreeken MV, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225.
11. Colwell JA, Winocour PD, Halushka PV. Do platelets have anything to do with diabetic microvascular disease? Diabetes 1983; 32 (suppl 2): 14-19.
12. O'Donnell MJ, Le Guen CA, Lawson N, Gyde OHB, Barnett AH. Platelet behaviour and haemostatic variables in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetic Med 1991; 8: 624-628.
13. Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor and PA activity. Thrombosis Res 1987; 46: 625-633.
14. Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995; 46: 715-718.
15. Allen RA, Kluft C, Brommer EJP. Acute effect of smoking on fibrinolysis: increase in the activity level of circulating extrinsic (tissue-type) plasminogen activator. Eur J Clin Invest 1984; 14: 354-361.
16. Potter van Loon BJ, de Bart ACW, Radder JK, Frölich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor (PAI-1) in humans. Fibrinolysis 1990; 4 (suppl 2): 93-94.
17. Hendriks HFJ, Veenstra J, Velthuis-te Wierik EJM, Schaafsma G, Kluft C. Effects of moderate dose of alcohol with evening meal on fibrinolytic factors. Br Med J 1994; 308: 1003-1006.
18. Kluft C, Verheijen JH, Rijken DC, Chang GTG, Jie AFH, Onkelinx C. Diurnal fluctuations in the activity of the fast-acting t-PA inhibitor. In: Davidson JF, Donati MB, Coccheri S, eds. Progress in Fibrinolysis, vol. VII. Edinburgh: Churchill Livingstone, 117-119.
19. Juhan-Vague I, Alessi MC, Fossat C, Declerck PJ, Kruithof EKO. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thrombosis and Haemostasis 1987; 58: 1096.
20. MacGregor IR, MacDonald S, Dawes J, Micklem LR, James K. A monoclonal antibody enzyme linked immunosorbent assay directed towards a fibrin binding region of tissuetype plasminogen activator. Fibrinolysis 1987; 1: 247-252.
21. MacGregor IR, Booth NA. An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI-1). Thrombosis and Haemostasis 1988; 59: 68-72.
22. Campbell MJ, Gardner MJ. Calculating confidence intervals for some non-parametric analyses. In: Gardner MJ, Altman DG, eds. Statistics with Confidence - Confidence Intervals and Statistical Guidelines, 1st edn. London: British Medical Journal Publications, 1989: 71-79.
23. Nilsson TK, Lithner F. Glycaemic control, smoking habits and diabetes duration affect the extrinsic fibrinolytic system in type 1 diabetic patients but microangiopathy does not. Acta Med Scand 1988; 224: 123-129.
24. Haitas B, Barnes AJ, Cederholm-Williams SA, Moore J, Shogry MEC, Turner RC. Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy. Diabetologia 1984; 27: 493-496.
25. Jensen T, Feldt-Rasmussen B, Bjerre-Knudsen J, Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989; 1: 461-463.
26. Lee P, Jenkins A, Bourke C, Santamaria J, Paton C, Janus E, Best J. Prothrombotic and antithrombotic factors are elevated in patients with type 1 diabetes complicated by microalbuminuria. Diabetic Med 1993; 10: 122-128.
27. Mahmoud R, Raccah D, Alessi MC, Aillaud I, Juhan-Vague I, Vague P. Fibrinolysis in insulin dependent diabetic patients with or without nephropathy. Fibrinolysis 1992; 6: 105-109.
28. Vicari AM, Viganó D'Angelo S, Testa S, Comi G, Galardi G, Orsi E, D'Angelo A. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus. Horm Metab Res 1992; 24: 516-519.
29. Walmsley D, Hampton KK, Grant PJ. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabetic Med 1991; 8: 954-959.
30. Ostermann H, Tschöpe D, Greber W, Meyer-Rüsenberg H-M, van de Loo, J. Enhancement of spontaneous fibrinolytic activity in diabetic retinopathy. Thrombosis and Haemostasis 1992; 68: 400-403.
31. McLaren M, Jennings PE, Forbes CD, Belch JJF. Fibrinolytic response to venous occlusion in diabetics with and without microangiopathy compared to normal age and sex matched controls. Fibrinolysis 1990; 4 (suppl 2): 95-96.
32. Wieczorek I, Pell ACH, Mclver B, MacGregor IR, Ludlam CA, Frier BM. Coagulation and fibrinolytic systems in type 1 diabetes: effects of venous occlusion and insulin-induced hypoglycaemia. Clinical Science 1993; 84: 79-86.
33. Simpson AJ, Booth NA, Moore NR, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol 1990; 75: 543-548.
34. Belch JJF, McArdle BM, Burns P, Lowe GDO, Forbes CD. The effects of acute smoking on platelet behaviour, fibrinolysis and haemorrheology in habitual smokers. Thrombosis and Haemostasis 1984; 51: 6-8.
35. Kjaeldgaard A, Larsson B. Long-term treatment with combined oral contraceptives and cigarette smoking associated with impaired activity of tissue plasminogen activator. Acta Obstet Gynecol Scand 1986; 65: 219-222.
36. Facchini FS, Hollenbeck CB, Jeppesen J, Chen Y-DI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
37. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein, MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism: Clinical and Experimental 1993; 42: 945-949.
38. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations; an analysis of published data. Br Med J 1989; 298: 784-788.
39. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825.
40. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arteriosclerosis and Thrombosis 1994; 14: 1264-1271.